Holger Reithinger

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

OMEICOS Therapeutics is a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company's novel therapeutic strategy is based upon the discovery of natural CYP-P450 generated metabolites of omega-3 fatty acids, so called epoxyeicosanoids. This new class of bioactive lipid mediators activates type specific cellular endogenous pathways that can be therapeutically deployed in inflammatory, cardiovascular, and other diseases. OMEICOS has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids. These small molecules are orally available and show significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts. The first development project makes use of the strong anti-arrhythmic effect of the compounds for the development of an oral therapy for atrial fibrillation. In contrast to all other anti-arrhythmic drugs that act almost exclusively via direct inhibition of ion channels, OMEICOS'​ substances activate an endogenous cardio-protective signalling pathway that not only stabilizes the heart rhythm, but also provides curative effects to the diseased organ by preventing its electrical and structural remodelling. OMEICOS was founded as a spin-off from the Max-Delbrück-Center in Berlin. Its technology is based on ground breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders Drs. Wolf-Hagen Schunck, John. R. Falck, Dominik Müller and Robert Fischer.

Allecra Therapeutics, founded in 2013, is a private, clinical-stage biopharmaceutical company developing novel therapies to combat antibiotic resistance by overcoming emergent resistance mechanisms. Lead product candidate, cefepime/enmetazobactam, has shown superiority over standard of care in patients with complicated urinary tract infections (cUTIs) in a randomized, controlled, double-blind, global Phase 3 trial, and the Company is preparing submissions for marketing approval in the U.S. and EU based on these results. The Company has significant patent protection covering proprietary enmetazobactam in major territories. Allecra’s investors are: Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMedPartners. Allecra’s wholly owned French subsidiary is a beneficiary of financial support from Bpifrance and the Région Alsace.

Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Our technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes. We are applying our proprietary know-how to develop a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.

OMEICOS Therapeutics is a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company's novel therapeutic strategy is based upon the discovery of natural CYP-P450 generated metabolites of omega-3 fatty acids, so called epoxyeicosanoids. This new class of bioactive lipid mediators activates type specific cellular endogenous pathways that can be therapeutically deployed in inflammatory, cardiovascular, and other diseases. OMEICOS has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids. These small molecules are orally available and show significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts. The first development project makes use of the strong anti-arrhythmic effect of the compounds for the development of an oral therapy for atrial fibrillation. In contrast to all other anti-arrhythmic drugs that act almost exclusively via direct inhibition of ion channels, OMEICOS'​ substances activate an endogenous cardio-protective signalling pathway that not only stabilizes the heart rhythm, but also provides curative effects to the diseased organ by preventing its electrical and structural remodelling. OMEICOS was founded as a spin-off from the Max-Delbrück-Center in Berlin. Its technology is based on ground breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders Drs. Wolf-Hagen Schunck, John. R. Falck, Dominik Müller and Robert Fischer.

HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry. With its experienced investment team, HTGF supports start-ups in all phases of their development into international market leaders. HTGF invests in pre-seed and seed phases and can participate significantly in later-stage financing rounds. Since its inception in 2005, HTGF has financed approx. 800 start-ups and successfully sold shares in 200 companies. HTGF has over 2 billion euros of fund volume. Fund investors in the public-private partnership include the German Federal Ministry of Economics and Energy, KfW Capital and 45 companies.

Cellnovo is an innovative medical technology company specialising in diabetes. The company develops and markets The Cellnovo System, the world's first mobile, connected, all-in-one diabetes management system that helps make life easier for people with type 1 diabetes. Compact, intuitive and entirely connected, Cellnovo’s micro-pump for insulin delivery communicates wirelessly with a locked-down Android phone, offering the quality and responsiveness that is to be expected from consumer-grade smartphones, while preserving the high-level of security of a medical-grade device. This unique device allows optimal management of diabetes whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. The current version of the system has received CE Mark approval and is reimbursed and available in 10 countries: France, the United Kingdom, The Netherlands, Italy, Spain, Australia, New Zealand, Israel, Greece and Cyprus. Cellnovo has a clearly-defined expansion strategy that involves accelerating the product’s commercialisation, initially in Europe and then in the United States and Asia, and increasing its production capacity to respond to a high level of demand. For more information, visit www.cellnovo.com.